Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 730

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 730
---
 obligations under the Transaction Agreements (such delay or hindrance, a “Purchaser Adverse Effect”).

4.4 . All consents, approvals, orders and authorizations required on the
part of such Purchaser in connection with the execution, delivery or performance of this Agreement, the issuance of the Securities and the consummation of the other transactions contemplated herein have been obtained or made, other than such
consents, approvals, orders and authorizations the failure of which to make or obtain, individually or in the aggregate, would not reasonably be expected to have a Purchaser Adverse Effect.

4.5 . Such Purchaser’s residence (if an individual) or offices in which its investment
decision with respect to the Securities was made (if an entity) are located at the address immediately below such Purchaser’s name on .

4.6 . Such Purchaser has not retained, utilized or been represented by any broker or
finder in connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay.

4.7 . Each Purchaser hereby represents and warrants that, it (i) as of the date hereof is, and on each date on which it exercises the Pre-Funded
Warrants, will be, if an entity,

D-15

is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an institutional “accredited investor” as that term is defined in Rule 501(a) under
Regulation D promulgated pursuant to the Securities Act; or (ii) if an individual, is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act and has such knowledge and experience in
financial and business matters as to be able to protect such Purchaser’s own interests in connection with an investment in the Securities. Each Purchaser further represents and warrants that (x) such Purchaser is capable of evaluating the
merits and risk of such investment, and (y) is an “institutional account” as defined by FINRA Rule 4512(c). Such Purchaser understands and agrees that the offering and sale of the Securities has not been registered under the
Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment
intent and the accuracy of such Purchaser’s representations as expressed herein.

4